A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Advanced Solid Tumors Cancer Interventions: Drug: ABBV-368; Drug: Tilsotolimod; Drug: Nab-paclitaxel; Drug: ABBV-181 Sponsors: AbbVie; Idera Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma | Study